Cas:180675-22-3 (1,3-dioxolan-2-ylmethyl)magnesium bromide manufacturer & supplier

Chemical Name:(1,3-dioxolan-2-ylmethyl)magnesium bromide

CAS.NO:180675-22-3

Synonyms:MFCD01321271;(1,3-Dioxolan-2-ylmethyl)magnesium bromide solution;(1,3-Dioxolan-2-ylmethyl)magnesium bromide

Molecular Formula:C₄H₇BrMgO₂

Molecular Weight:191.30600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:65-67ºC

Density:0.938 g/mL at 25ºC

Index of Refraction:

PSA:18.46000

Exact Mass:189.94800

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 2924 3/PG 2

Packing Group:

Contact us for information like MFCD01321271 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(1,3-Dioxolan-2-ylmethyl)magnesium bromide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD01321271 Use and application,(1,3-Dioxolan-2-ylmethyl)magnesium bromide solution technical grade,usp/ep/jp grade.

Related News: Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. (1,3-dioxolan-2-ylmethyl)magnesium bromide manufacturer On Friday, the Trump administration announced it will deny entry to foreign nationals who have traveled in China in the last 14 days, starting Sunday. (1,3-dioxolan-2-ylmethyl)magnesium bromide supplier AXON is planning a follow-up trial that will include a better-defined group of Alzheimer’s patients suffering from both amyloid plaques and tau tangles, Novak said. (1,3-dioxolan-2-ylmethyl)magnesium bromide vendor A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. (1,3-dioxolan-2-ylmethyl)magnesium bromide factory A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting.